Status:
COMPLETED
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Ext...
Eligibility Criteria
Inclusion
- Diagnosis of advanced/metastatic lung cancer
Exclusion
- Previous treatment with chemotherapy
- Uncontrolled diabetes
- History/active cardiovascular disease
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
282 Patients enrolled
Trial Details
Trial ID
NCT00147537
Start Date
February 1 2005
End Date
August 1 2011
Last Update
October 30 2013
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Tucson, Arizona, United States, 85719
2
Pfizer Investigational Site
Tucson, Arizona, United States, 85724-5024
3
Pfizer Investigational Site
Tucson, Arizona, United States, 85724
4
Pfizer Investigational Site
Greenbrae, California, United States, 94904